Introducing Tradu: a Powerful New Multi-asset Trading Platform
Tradu is a new, sophisticated multi-asset trading platform for the active trader and investor offering thousands of tradable assets* across listed equities, commodities, cryptocurrencies, CFDs, forex, treasuries and indices. The platform will launch in the UK in December before rolling out globally over the coming months. Tradu is part of Stratos Group International, LLC (“Stratos”), a wholly owned subsidiary of Jefferies Financial Group Inc. (“Jefferies”) (NYSE: JEF).
Historically, multi-asset trading has involved either having many accounts and mobile apps or using one confusing platform with a disjointed experience for each asset class. Tradu is redefining the trading industry by providing clients with an intuitive and advanced platform with a superior trading experience across each of the tradable markets, all from one portal that can be accessed via a mobile app and web platforms.
The multi-asset trading platform offers trading in listed equities, cryptocurrency markets and CFD trading, with the ability to apply leverage on stocks, indices, commodities, forex and cryptocurrencies*. In addition to multi-asset trading, Tradu’s eWallet* provides clients with the convenience of a virtual and physical debit card as well as seamless transfers between trading and eWallet accounts.
Tradu combines deep market access, state-of-the-art technology, decades of trading expertise and institutional-level pricing to offer an innovative platform that active traders and investors deserve. Clients can trade a range of assets on both a leveraged and unleveraged basis, with competitive and transparent pricing and personalised support with capable and accessible, human customer service.
Brendan Callan, CEO commented: “Tradu has been built by traders for traders to provide them with the platform they deserve - one that offers access to a variety of markets, all from one seriously powerful, sleek app. Too much of the retail trading industry has focused on gimmicky features, trend-chasing and gamification. Instead, we are laser focused on serving traders’ needs, offering aggressively competitive pricing, professional trading tools and a client service team that strives for excellence. Tradu is launching the next evolution of mobile trading to UK clients and will soon be expanding globally.”
Sign up at www.tradu.com for more information and to be notified as soon as Tradu goes live in your region.
ENDS
*Products and services offered vary by region
About Tradu
Tradu is headquartered in London with offices around the world. The global Tradu team speaks more than two dozen languages and prides itself on its responsive and helpful client support.
Stratos also operates FXCM, an FX and CFD platform founded in 2001. Stratos will continue to offer FXCM services alongside Tradu’s multi-asset platform.
Stratos subsidiaries are authorised and regulated in the UK, Europe, Australia and South Africa.
©2023 Stratos Group International, LLC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122534754/en/
Contact information
Nick Murray-Leslie/Michael Deeny
Chatsworth Communications
+44 (0) 20 7440 9780
TraduPR@chatsworthcommunications.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom